Zobrazeno 1 - 10
of 470
pro vyhledávání: ''
Autor:
Pascale Gaussem, Jérôme Duchemin, Michaela Fontenay, Elisabeth Mazoyer, Georges Jourdi, Christilla Bachelot-Loza, Sonia Poirault-Chassac
Publikováno v:
Thrombosis Research. 183:159-162
Introduction Clinical benefit-risk balance of direct oral anticoagulants (DOAC) in atherothrombosis prevention differs between anti-Xa and anti-IIa drugs and their specific effect on platelet functions remains controversial. We hence investigated riv
Autor:
Maria Jastrzębska, Barbara Dołęgowska, Anna Lebiecka, Jarosław Woźniak, Zuzanna Marcinowska, Marta Budkowska
Publikováno v:
Thrombosis Research. 182:79-88
In this paper we tested a group of 66 healthy volunteers in terms of the influence of circadian rhythm on selected parameters of the coagulation system and fibrinolytic system. Blood was collected at 6-hour intervals, at 8 am, 2 pm, 8 pm and 2 am. Ci
Autor:
Junjie Kou, Haijiao Jing, Jialan Shi, Jingwen Du, Chunxu Wang, Muxin Yu, Yayan Bi, Jin Zhou, Xinyi Zhao, Valerie A. Novakovic, Yueyue Li, Yan Zhang, Zengxiang Dong
Publikováno v:
Thrombosis Research. 180:87-97
Patients with colorectal cancer (CRC) are at increased risk of venous thrombosis, but the precise mechanisms of thrombogenesis in CRC remain largely unknown. We aimed to identify the novel role of neutrophil extracellular traps (NETs) in the inductio
Publikováno v:
Thrombosis Research. 180:74-85
Background The incretin hormone Glucagon-like peptide 1(GLP-1) plays a pivotal role in maintaining glucose homeostasis with effects also on the cardiovascular system. GLP-1 influences platelet functions by increasing the inhibitory action of nitric o
Autor:
Lidija Covic, Navin K. Kapur, Andrew Weintraub, Ping Zhang, Layla Van Doren, Vilma Castaneda, Ryan Stevenson, Athan Kuliopulos, James Perkins, Carey Kimmelstiel, Nga Nguyen
Publikováno v:
Thromb Res
ACS patients undergoing percutaneous coronary intervention (PCI) when treated with bivalirudin and clopidogrel had increased frequency of early stent thrombosis. 24 patients referred for intervention with planned bivalirudin therapy, not previously t
Publikováno v:
Thrombosis Research. 177:51-58
Platelet-tumour cell interaction is implicated in the initiation of breast cancer-associated thrombosis, with hormone-therapy (Tamoxifen/Anastrozole), increasing this risk. However, recent in vitro research indicates that Tamoxifen inhibits platelet
Autor:
Claire Roome, Scott Harris, Rod Stables, Nick Curzen, Ian Kemp, Vikram Khanna, Adeel Shahzad, Christine Mars, Keith Wilson, Kala Thayalasamy, Rob Cooper
Publikováno v:
THROMBOSIS RESEARCH
In randomised trials, bivalirudin has been associated with higher rates of acute stent thrombosis (AST) compared to unfractionated heparin (UFH), without mechanistic explanation. Furthermore, data are discrepant regards the antiplatelet effects of bi
Autor:
Kevin P. Cohoon, Rowlens M. Melduni, Matylda Mazur, Robert D. McBane, Ewa Konik, Naser M. Ammash, Izabeal Gosk-Bierska, Thomas G. McLeod, Waldemar E. Wysokinski, Thomas M. Munger
Publikováno v:
Thrombosis Research. 172:4-8
Background P-selectin - a biomarker of platelet and endothelial cell activation is elevated in patients with non-valvular atrial fibrillation (NVAF). However, the association between sP-selectin level and thromboembolic complications in NVAF patients
Autor:
Dimitrios Venetsanos, Håkan Wallén, Sofia Sederholm Lawesson, Eva Swahn, Joakim Alfredsson, David Erlinge, Kerstin M. Gustafsson, Tomas L. Lindahl
Publikováno v:
Thrombosis Research. 171:38-44
Background: It remains unknown if bivalirudin compared to heparin confers any additional inhibition of platelet and coagulation activation during primary percutaneous coronary intervention (PPCI) after pretreatment with ticagrelor. Methods: In this s
Autor:
Yuansheng Fan, Juan Li, Chunjian Li, Jing Zhang, Lianghong Ying, Yi Lu, Zihao Zhou, Fei Wang, Xiaoxuan Gong, Lu Yang, Lianlian Mei, Ke Xu
Publikováno v:
Thrombosis Research. 167:119-124
Background Hepatitis B virus (HBV) infection has been reported to down-regulate the expression of CYP2C19 gene, which may decrease the bioactivation of clopidogrel into active metabolites. We aimed to evaluate the impact of HBV infection on platelet